用于放免治疗的核素研究进展

张弘

用于放免治疗的核素研究进展

张弘

文章导航 > 国际放射医学核医学杂志 > 2003, 27 > 4: (148-150,161)

引用本文:

Citation:

用于放免治疗的核素研究进展

张弘

510120 广州, 中山大学附属第二医院核医学科

作者简介: 张弘(1967-),男,硕士研究生,主要从事核素显像和治疗的研究。;

中图分类号: R817.5

Advances in radionuclide for radioimmunotherapy

ZHANG Hong

Department of Nuclear Medicine, The Second Affiliated Hospital of Sun Yat-sun University, Guangzhou 510120, China
CLC number: R817.5

摘要: 放射免疫治疗肿瘤具有独特优势,许多新的核素被用于制备肿瘤放免治疗药物。高能α、β粒子及抗肿瘤导向载体的应用促进了放免治疗药物的发展。本文介绍了用于放射免疫治疗的核素最新研究进展,归纳了用于放射免治疗的常用放射性核素,并比较了各自的优缺点,指出了放射性核素用于放射免疫治疗过程中存在的问题、可能的解决方法及今后的发展趋势。
- 放射免疫治疗 /
- 核素 /
- 肿瘤
Abstract: Radioimmunotherapy (RIT)has superiority in treatment of cancer.the application of high energy α emmiter,β emmiter,electron capture radioisotopes and anti-cancer target carriers bring an innovation of RIT drugs.In this paper,it describes in detail the advances in radionuclide for RIT in the therapy of cancer and introduces the radionuclides,compares their advantages and disadvantages,and finally discusses the problems,potential solutions and directions in developing of radionuclide for RIT.
- Radioimmunotherapy /
- radionuclide /
- cancer
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Allen BJ. Targeted alpha therapy: evidence for potential efficacy of alpha immunoconjugates in the management of micrometastatic cancer[J]. J Australia Radiol, 1999, 43: 480-486.
[2]	McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha emitting nuclides[J]. Eur J Nucl Med, 1998, 25: 1341-1351.
[3]	Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: ²¹³Bi-HuM195(anti-CD33) in patients with leukemia[J]. J Nucl Med, 1999, 40: 1935-1946.
[4]	Couturier O, Faivre C A, Filippovich IV, et al. Validation of ²¹³Bi alpha radioimmunotherapy for multiple myeloma[J].Clin Cancer Res, 1999, 5: 3165s-3170s.
[5]	Palm S, BackT, Claesson I, et al. Effects of the alpha particle emitter At-211 and low dose rate gamma radiation on the human cell line Colo-205 as studies with a growth assay[J]. Anticancer Res, 1998, 18: 1671-1676.
[6]	Gautherot E, Rouvier E, Danel L, et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and ¹³¹I labeled bivalent hapten[J]. J Nucl Med, 2000, 41: 480-487.
[7]	Wisernan GA, Write CA, Stabin M, et al. Phase Ⅰ/Ⅱ ⁹⁰Y-zevalin radioimmunotherapy dosimetry result in relapsed or refractory non-Hodgkin's lymphoma[J]. Eur J Nuel Med,2000, 27: 766-777.
[8]	O'Donnell RT, Shen S, Denardo SJ, et al. A phase I study of ⁹⁰Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma[J]. Anticancer Res, 2000, 20: 3647-3655.
[9]	Kinuya S, Yokoyama K, Kawashima A, et al. Radioimmunotherapy with ¹⁸⁶Re-labeled mono-clonal antibody to treat liver metastases of colon cancer cells in nude mice[J].Cancer Biother Radiopharm, 2002, 17: 681-687.
[10]	Lou C, Chen ZN, Bian HJ, et al. Pharmacokinetics of radioimmunotherapeulic agent of direct labeling mAb ¹⁸⁸Re-HAb18[J]. World J Gastroenterol, 2002, 8: 69-73.
[11]	Iznaga-Escobar N. Direct radiolabeling of mon-oclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors-a review of radiolabeling characteristics,quality control and in vitro stability studies[J]. Appl Radiat Isot,2001, 54: 399-406.
[12]	Gestin JF, Loussouarn A, Bardies M, et al. Two step targeting of xenografted colon carcinoma using a bispecific antibody and ¹⁸⁸Re labeled bivalent hapten: biodistribution and dosimetry studies[J]. J Nucl Med, 2001, 42: 146-153.
[13]	Denardo GL, Denardo SJ, Donnell RT, et al. Are Radiometal labeled antibodies better than iodine-131-1abeled antibodies: comparative pharmacokinetics and dosimetry of copper 67, iodine 131 and yttrium 90 labeled lyre-1 antibody in patients with non-Hodgkin's lymphoma[J]. Clin Lymphoma,2000, 1: 118-126.
[14]	Neves M, Kling A, Lambrecht RM. Radionuclide production for therapeutic radiopharmaceuticalsp[J]. Appl Radiat Isot,2002, 57: 657-664.
[15]	Ward RL, Packham D, Smythe AM, et al. Phase I clinical trial of the chimeric monoclonal antibldy (c30.6) in patients with metastatic colorectal cancer[J]. Clin Cancer Res, 2000,6: 4674-4683.
[16]	Chrastina A, Pastorekova S, Pastored J. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by ¹²⁵I-labeled M75 monoclonal antibody[J]. Neoplasma, 2003, 50: 13-21.

[1]	杨卫东 , 汪静 . 肿瘤核素靶向治疗新进展. 国际放射医学核医学杂志, 2015, 39(1): 19-24, 36. doi: 10.3760/cma.j.issn.1673-4114.2015.01.006
[2]	田嘉禾 . 关于放射免疫治疗的新思考. 国际放射医学核医学杂志, 1997, 21(z1): 249-252.
[3]	田源 , 张良安 . 放射免疫治疗中的α核素微剂量研究. 国际放射医学核医学杂志, 2006, 30(1): 39-41.
[4]	杨连君 , 司晓辉 , 隋延仿 , 陈志南 , 管昌田 . ⁹⁰Y标记单克隆抗体导向治疗肿瘤. 国际放射医学核医学杂志, 1996, 20(5): 205-207.
[5]	崔瑞雪 , 卢倜章 . ⁹⁰Y在肿瘤治疗中的应用. 国际放射医学核医学杂志, 1996, 20(5): 208-211.
[6]	袁志斌 . Zevalin^TM:一种放射免疫治疗新药. 国际放射医学核医学杂志, 2002, 26(5): 225-227.
[7]	李敏杰 . 胰腺癌的放射免疫治疗进展. 国际放射医学核医学杂志, 2003, 27(4): 154-156.
[8]	向艳 , 夏劲松 . 生长抑素类似物及其标记核素. 国际放射医学核医学杂志, 2002, 26(1): 21-24.
[9]	高云朝 . 恶性胶质瘤的放射免疫治疗. 国际放射医学核医学杂志, 2004, 28(4): 149-152.
[10]	郑建国 , 谭天秩 . 放射性核素反义治疗在恶性肿瘤中的应用. 国际放射医学核医学杂志, 1998, 22(6): 242-244.

点击查看大图

计量

文章访问数: 1057
HTML全文浏览量: 118
PDF下载量: 2

用于放免治疗的核素研究进展

张弘

作者简介:张弘(1967-),男,硕士研究生,主要从事核素显像和治疗的研究。

510120 广州, 中山大学附属第二医院核医学科

收稿日期: 2003-03-09

关键词:

放射免疫治疗 /
核素 /
肿瘤

摘要: 放射免疫治疗肿瘤具有独特优势,许多新的核素被用于制备肿瘤放免治疗药物。高能α、β粒子及抗肿瘤导向载体的应用促进了放免治疗药物的发展。本文介绍了用于放射免疫治疗的核素最新研究进展,归纳了用于放射免治疗的常用放射性核素,并比较了各自的优缺点,指出了放射性核素用于放射免疫治疗过程中存在的问题、可能的解决方法及今后的发展趋势。